false 0001771706 A1 0001771706 2025-05-09 2025-05-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 9, 2025

 

VIREO GROWTH INC.

(Exact name of registrant as specified in its charter)

 

British Columbia

(State or other jurisdiction of Incorporation)

 

000-56225   82-3835655
(Commission File Number)   (IRS Employer Identification No.)
     

207 South 9th Street

Minneapolis, Minnesota

  55402
(Address of principal executive offices)   (Zip Code)

 

(612) 999-1606

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
N/A N/A N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On May 9, 2025, Vireo Growth Inc. (the “Company”) issued a press release to report its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto.

 

The information in this Item 2.02 and in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. The information in this this Item 2.02 and in Exhibit 99.1 shall not be deemed to be incorporated by reference into any filing of the Company whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release, dated as of May 9, 2025**
99.2   Investor Presentation, dated as of May 9, 2025**
104   Cover Page Interactive Data File (embedded within Inline XBRL document)

 

**Furnished herewith

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  VIREO GROWTH INC.
  (Registrant)
   
  By: /s/ Tyson Macdonald
    Tyson Macdonald
    Chief Financial Officer

 

Date: May 9, 2025

 

 

 

 

Exhibit 99.1

 

 

 

Vireo Growth Inc. Announces First Quarter 2025 Results

 

– Q1 revenue of $24.5 million increased 1.9% year-over-year, in line with expectations for Vireo’s established markets –

 

– Merger Transactions expected to begin closing in Q2 and further strengthen profitability profile –

 

MINNEAPOLIS May 9, 2025 Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today reported financial results for its first fiscal quarter ended March 31, 2025. Key financial results are presented below in summary form with supporting commentary and discussion from management of certain key operating metrics which the Company uses to judge its performance. All currency figures referenced herein are denominated in U.S. dollars.

 

Summary of Key Financial Metrics

 

   Three Months Ended 
US $ in millions  March 31, 
   2025   2024   Variance 
GAAP Revenue  $24.5   $24.1    1.9%
GAAP Gross Profit  $12.4   $12.2    1.4%
Gross Profit Margin   50.6%   50.8%   -20 bps
SG&A Expenses  $7.5   $7.1    6.0%
SG&A Expenses (% of Sales)   30.5%   29.3%   120bps
Operating Income (Loss)  $2.0   $4.8    -58.5%
Operating Income Margin   8.1%   19.8%   -1,170bps
Adjusted EBITDA  $6.6   $6.1    8.5%
Adjusted EBITDA Margin   26.8%   25.2%   160bps

 

Management Commentary

 

Chief Executive Officer John Mazarakis commented, “First quarter results were in line with our expectations for Vireo’s established markets. We experienced continued growth in Maryland, stable performance in Minnesota, medical sales declines in New York, and the commencement of New York adult use sales from our indoor facility. We remain focused on closing our pending merger transactions, expected to begin during the second quarter.”

 

 

 

 

Balance Sheet and Liquidity

 

As of March 31, 2025, total current assets excluding New York assets held for sale were $128.5 million, including cash on hand of $86.3 million. Total current liabilities excluding New York assets held for sale and uncertain tax liabilities were $13.3 million. As of March 31, 2025, the Company had a total of 472,078,412 shares outstanding on the treasury method basis using a share price of $0.45.

 

Merger Transactions

 

On March 21, 2025, the Company announced that it filed its Definitive Information Circular with respect to its proposed Merger Transactions. The Circular contains proforma financial information for the combined company as well as 2023 and 2024 audited financial information for each of the various Merger Transaction targets. The Company also announced that it has received requisite shareholder approval in connection with the Merger Transactions after soliciting shareholder approvals via written consent.

 

The Company has obtained required regulatory approvals for its proposed Utah transactions (“Wholesome Cannabis” and the “Arches” technology platform) and is working toward satisfying all other customary closing conditions of the Merger Transactions, which it expects to meet during the second quarter of 2025.

 

Conference Call and Webcast Information

 

Vireo management will host a conference call with research analysts today, May 9, 2025, at 8:30 a.m. ET (7:30 a.m. CT) to discuss its financial results for its first quarter ended March 31, 2025. Interested parties may attend the conference call by dialing 1-888-672-2415 (Toll-Free) (US and Canada) or 1-646-307-1963 (Toll) (International) and referencing conference ID number 3718174.

 

A live audio webcast of this event will also be available in the Events & Presentations section of the Company’s Investor Relations website and via the following link: https://events.q4inc.com/attendee/968886697.

 

About Vireo Growth Inc.

 

Vireo was founded as a pioneer in medical cannabis in 2014 and we are fueled by an entrepreneurial drive that sustains our ongoing commitment to serve and delight our key stakeholders, most notably our customers, our employees, our shareholders, our industry collaborators, and the communities in which we live and operate. We work every day to get better and our team prioritizes 1) empowering and supporting strong local market leaders and 2) strategic, prudent capital and human resource allocation. For more information, please visit www.vireogrowth.com.

 

Additional Information

 

Additional information relating to the Company’s first quarter 2025 results will be available on EDGAR and SEDAR later today. Vireo refers to certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA in circumstances in which the Company believes that doing so provides additional perspective and insights when analyzing the core operating performance of the business. These measures do not have any standardized meaning and may not be comparable to similar measures presented by other issuers. Please see the Supplemental Information and Reconciliation of Non-GAAP Financial Measures at the end of this news release for more detailed information regarding non-GAAP financial measures.

 

 

 

 

Contact Information

 

Joe Duxbury

Chief Accounting Officer

investor@vireogrowth.com

(612) 314-8995

 

Forward-Looking Statement Disclosure

 

This press release contains “forward-looking information” within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes “financial outlooks” within the meaning of applicable United States or Canadian securities laws, this information is being provided as preliminary financial results; the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as “should,” “believe,” “estimate,” “would,” “looking forward,” “may,” “continue,” “expect,” “expected,” “will,” “likely,” “subject to,” “transformation,” and “pending,” variations of such words and phrases, or any statements or clauses containing verbs in any future tense and includes statements regarding the Company’s expected performance in 2025; the Company’s pending merger transactions, including the expected timing of the closing of such mergers; future shareholder returns; the Company’s future access to liquidity; future growth opportunities for the Company; . These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein and in our Annual Report on Form 10-K filed with the Securities Exchange Commission. Our actual financial position and results of operations may differ materially from management’s current expectations and, as a result, our revenue, EBITDA, Adjusted EBITDA, and cash on hand may differ materially from the values provided in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

 

 

 

 

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: risks related to the Company’s pending mergers, including satisfaction of closing conditions and regulatory and shareholder approval; risks related to the timing and content of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business; liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company’s ability to meet the demand for flower in Minnesota; risk of failure in the lawsuit with Verano and the cost of that litigation; our ability to dispose of our assets held for sale at an acceptable price or at all; and risk factors set out in the Company's Form 10-K for the year ended December 31, 2024, which is available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com.

 

The statements in this press release are made as of the date of this release. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.

 

Supplemental Information

 

The financial information reported in this news release is based on unaudited financial statements for the first quarter ended March 31, 2025, and March 31, 2024. All financial information contained in this news release is qualified in its entirety with reference to such financial statements. To the extent that the financial information contained in this news release is inconsistent with the information contained in the Company’s audited financial statements, the financial information contained in this news release shall be deemed to be modified or superseded by the Company’s audited financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws.

 

 

 

 

VIREO GROWTH INC.

CONSOLIDATED BALANCE SHEETS AS OF 3/31/2025 AND 12/31/2024

(Amounts Expressed in United States Dollars, Unaudited and Condensed)

 

   March 31,   December 31, 
   2025   2024 
Assets          
Current assets:          
Cash  $86,260,997   $91,604,970 
Accounts receivable, net of credit losses of $259,011 and $254,961, respectively   3,983,466    4,590,351 
Income tax receivable   11,367,067    12,027,472 
Inventory   23,343,300    21,666,364 
Prepayments and other current assets   1,785,664    1,650,977 
Warrants held   1,751,906    2,270,964 
Assets Held for Sale   99,941,960    96,560,052 
Total current assets   228,434,360    230,371,150 
Property and equipment, net   32,836,175    32,311,762 
Operating lease, right-of-use asset   7,660,568    7,859,434 
Intangible assets, net   7,694,517    7,899,328 
Deposits   421,244    421,244 
Total assets  $277,046,864   $278,862,918 
Liabilities          
Current liabilities          
Accounts payable and accrued liabilities  $12,197,467   $10,456,036 
Long-Term debt, current portion       900,000 
Right of use liability   1,148,991    1,400,015 
Uncertain tax liability   34,959,000    33,324,000 
Liabilities held for sale   89,351,157    89,387,203 
Total current liabilities   137,656,614    135,467,254 
Right-of-use liability   16,437,288    16,494,439 
Other long-term liabilities   37,278    37,278 
Convertible debt, net   9,874,521    9,862,378 
Long-Term debt, net   62,603,583    61,438,046 
Total liabilities  $226,609,284   $223,299,395 
Stockholders’ deficiency          
Subordinate Voting Shares ($- par value, unlimited shares authorized; 339,475,288 shares issued and outstanding at March 31, 2025 and 337,512,681 at December 31, 2024)        
Multiple Voting Shares ($- par value, unlimited shares authorized; 278,170 shares issued and outstanding at March 31, 2025 and 285,371 at December 31, 2024)        
Additional paid in capital   288,381,930    286,999,084 
Accumulated deficit   (237,944,351)   (231,435,561)
Total stockholders' equity (deficiency)  $50,437,579   $55,563,523 
Total liabilities and stockholders' deficiency  $277,046,864   $278,862,918 

 

 

 

 

VIREO GROWTH INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

THREE MONTHS ENDED MARCH 31, 2025 AND 2024

(Amounts Expressed in United States Dollars, Unaudited and Condensed)

 

   Three Months Ended 
   March 31, 
   2025   2024 
Revenue  $24,540,641   $24,087,315 
Cost of sales          
Product costs   11,695,329    12,146,888 
Inventory valuation adjustments   433,000    (304,000)
Gross profit   12,412,312    12,244,427 
Operating expenses:          
Selling, general and administrative expenses   7,473,943    7,051,613 
Transaction related expenses   1,244,696     
Stock-based compensation expenses   1,460,850    179,789 
Depreciation   77,102    73,547 
Amortization   180,032    180,034 
Total operating expenses   10,436,623    7,484,983 
           
Gain (loss) from operations   1,975,689    4,759,444 
           
Other income (expense):          
Interest expenses, net   (7,599,517)   (8,722,637)
Impairment of long-lived assets        
Gain (loss) on disposal of assets       (120,856)
Other income (expenses)   790,038    1,317,589 
Other income (expenses), net   (6,809,479)   (7,525,904)
           
Loss before income taxes   (4,833,790)   (2,766,460)
           
Current income tax expenses   (1,675,000)   (3,945,000)
Deferred income tax recoveries        
Net loss and comprehensive loss   (6,508,790)   (6,711,460)
Net loss per share - basic and diluted  $(0.02)  $(0.05)
Weighted average shares used in computation of net loss per share - basic & diluted   366,800,177    143,126,330 

 

 

 

 

VIREO GROWTH INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

THREE MONTHS ENDED MARCH 31, 2025 AND 2024

(Amounts Expressed in United States Dollars, Unaudited and Condensed)

 

   MARCH 31, 
   2025   2024 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net loss  $(6,508,790)  $(6,711,460)
Adjustments to reconcile net loss to net cash used in operating activities:          
Inventory valuation adjustments   433,000    (304,000)
Depreciation   77,102    73,547 
Depreciation capitalized into inventory   545,262    560,180 
Non-cash operating lease expense   121,038    103,564 
Amortization of intangible assets   180,032    180,034 
Amortization of intangible assets capitalized into inventory   24,778    24,778 
Stock-based payments   1,321,220    179,789 
Warrants held   519,058    (1,327,879)
Interest Expense   1,213,681    2,015,889 
Accretion   50,284    52,815 
Loss (gain) on disposal of assets       120,856 
Change in operating assets and liabilities:          
Accounts Receivable   606,886    348,817 
Prepaid expenses   (134,688)   290,106 
Inventory   (2,032,109)   299,252 
Income taxes   660,406    175,203 
Uncertain tax position liabilities   1,635,000    3,760,000 
Accounts payable and accrued liabilities   1,818,743    174,340 
Changes in operating lease liabilities   (358,459)   (168,746)
Change in assets and liabilities held for sale   (3,495,266)   (1,037,417)
Net cash provided by (used in) operating activities  $(3,322,822)  $(1,190,332)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
PP&E Additions  $(1,146,777)  $(899,264)
Deposits       (150,100)
Net cash provided by (used in) investing activities  $(1,146,777)  $(1,049,364)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from warrant exercises   38,516     
Proceeds from option exercises   23,110     
Debt principal payments   (936,000)   (1,050,000)
Lease principal payments       (71,066)
Net cash provided by (used in) financing activities  $(874,374)  $(1,121,066)
           
Net change in cash  $(5,343,973)  $(3,360,762)
           
Cash, beginning of year  $91,604,970   $15,964,665 
           
Cash, end of year  $86,260,997   $12,603,903 

 

 

 

 

VIREO GROWTH INC.

STATE-BY-STATE REVENUE PERFORMANCE

THREE MONTHS ENDED MARCH 31, 2025 AND 2024

 

   Three Months Ended         
   March 31,         
   2025   2024   $ Change   % Change 
Retail:                
MN  $11,209,204   $10,977,089   $232,115    2%
NY   1,205,045    1,821,269    (616,224)   (34)%
MD   6,819,392    6,801,082    18,310    0%
Total Retail  $19,233,641   $19,599,440   $(365,799)   (2)%
                     
Wholesale:                    
MD   4,089,238    3,353,661    735,577    22%
NY   936,351    1,134,214    (197,863)   (17)%
MN   281,411        281,411    100%
Total Wholesale  $5,307,000   $4,487,875   $819,125    18%
                     
Total Revenue  $24,540,641   $24,087,315   $453,326    2%

 

 

 

 

Reconciliation of Non-GAAP Financial Measures

 

Vireo management occasionally elects to provide certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA. EBITDA and Adjusted EBITDA are a non-GAAP measure and does not have a standardized definition under GAAP. The following information provides reconciliations of the supplemental non-GAAP financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented.

 

Reconciliation of Net Loss to EBITDA and Adjusted EBITDA

 

   Three Months Ended 
   March 31, 
   2025   2024 
Net income (loss)  $(6,508,790)  $(6,711,460)
Interest expense, net   7,599,517    8,722,637 
Income taxes   1,675,000    3,945,000 
Depreciation & Amortization   257,134    253,581 
Depreciation and amortization included in cost of goods sold   570,040    584,958 
EBITDA (non-GAAP)  $3,592,901   $6,794,716 
Inventory adjustment  $433,000   $304,000 
Grown Rogue termination fee included in cost of goods sold   266,667     
Stock-based compensation   1,460,850    179,789 
Transaction related expenses   1,244,696     
Other income   (790,038)   (1,327,879)
Severance expense   379,916     
Loss on disposal of assets       120,856 
Adjusted EBITDA (non-GAAP)  $6,587,992   $6,071,482 

 

 

 

Exhibit 99.2

GRAPHIC

CSE: VREO OTCQX: VREOF Q1 2025 Results Conference Call May 9, 2025

GRAPHIC

Q1 2025 Results Conference Call || 2 Forward Looking Statement Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This presentation includes information, statements, beliefs, and opinions which are forward-looking, and which reflect current estimates, expectations, and projections about future events, referred to herein and which constitute “forward-looking statements” or “forward-looking information” within the meaning of Canadian and U.S. securities laws. Statements containing words such as “believe”, “expect”, “intend”, “should”, “seek”, “anticipate”, “will”, “positioned”, “plan”, “may”, “estimate”, “could”, “continue”, “outlook”, “strategy”, “initiative”, “foreseeable”, “potential”, “guidance”, “future”, “priorities”, “opportunity”, “likely”, or, in each case, their negative, plural, and words of similar meaning are intended to identify forward-looking statements. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions concerning, among other things, the Company’s anticipated business strategies, anticipated trends in the Company’s business and anticipated market share, that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. In addition, even if the outcome and financial effects of the plans and events described herein are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in subsequent periods. Although the Company has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated, or intended, including those described in the Risk Factors section of our Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission. Forward-looking information contained in this presentation is based on the Company’s current estimates, expectations and projections, which the Company believes are reasonable as of the current date. The Company can give no assurance that these estimates, expectations and projections will prove to have been correct. You should not place undue reliance on forward-looking statements, which are based on the information available as of the date of this document. Forward-looking statements contained in this document are made of the date of this presentation and, except as required by applicable law, the Company assumes no obligation to update or revise them to reflect new events or circumstances. Historical statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. In this regard, certain financial information contained herein has been extracted from, or based upon, information available in the public domain and/or provided by the Company. In particular historical results should not be taken as a representation that such trends will be replicated in the future. No statement in this document is intended to be nor may be construed as a profit forecast. CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION: To the extent any forward-looking information in this presentation constitutes “future-oriented financial information” or “financial outlooks” within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out above under the heading “Cautionary Note Regarding Forward-Looking Information”. Vireo’s actual financial position and results of operations may differ materially from management’s current expectations and, as a result, Vireo’s revenue and expenses may differ materially from the revenue and expenses profiles provided in this presentation. Such information is presented for illustrative purposes only and may not be an indication of Vireo’s actual financial position or results of operations. NON-GAAP FINANCIAL MEASURES: EBITDA and Adjusted EBITDA are non-GAAP measures and do not have standardized definitions under U.S. GAAP accounting principles. EBITDA represents net income (loss) adjusted to exclude interest, income taxes, depreciation, and amortization. This supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented.

GRAPHIC

First Quarter and Recent Business Highlights • Q1 results were in line with expectations for Vireo’s established core markets • Q1 performance was driven by continued growth in Maryland, stable performance in Minnesota, medical sales declines in New York, and the commencement of adult use sales in New York from our indoor facility • Q1 operating expenses include $1.2 million of transaction-related expenses • Adjusted EBITDA margins continue to exceed 25% • Company ended Q1 with $86.3 million in cash • Merger Transactions expected to begin closing in Q2 • Management will provide additional updates on its combined platform once Merger Transactions have closed Q1 2025 Results Conference Call || 3

GRAPHIC

Summary Financials Q1 2025 Results Conference Call || 4 Three Months Ended US $ in millions March 31, 2025 2024 Variance GAAP Revenue $24.5 $24.1 1.9% GAAP Gross Profit $12.4 $12.2 1.4% Gross Profit Margin 50.6% 50.8% -20 bps SG&A Expenses $7.5 $7.1 6.0% SG&A Expenses (% of Sales) 30.5% 29.3% 120 bps Operating Income (Loss) $2.0 $4.8 -58.5% Operating Income Margin 8.1% 19.8% -1,170 bps Adjusted EBITDA $6.6 $6.1 8.5% Adjusted EBITDA Margin 26.8% 25.2% 160 bps Summary of Key Financial Metrics

GRAPHIC

State-by-State Revenue Performance1 Q1 2025 Results Conference Call || 5 1Q25 1Q24 %∆ 1Q25 4Q24 %∆ Total Retail: $19,233,641 $19,599,440 (2) $19,233,641 $19,375,309 (1) Minnesota $11,209,204 $10,977,089 2 $11,209,204 $11,221,254 0 Maryland $6,819,392 $6,801,082 0 $6,819,392 $6,846,072 0 New York $1,205,045 $1,821,269 (34) $1,205,045 $1,307,983 (8) Total Wholesale: $5,307,000 $4,487,875 18 $5,307,000 $5,648,007 (6) Minnesota $281,411 -- 100 $281,411 $133,606 111 Maryland $4,089,238 $3,353,661 22 $4,089,238 $4,014,754 2 New York $936,351 $1,134,214 (17) $936,351 $1,499,647 (38) Total Revenue: $24,540,641 $24,087,315 2 $24,540,641 $25,023,316 (2) Q1 YoY Q1 Sequential 1 Please refer to form 10-Q for the three months ended March 31, 2025 for complete detail on state-by-state revenue performance including non-core markets and discontinued operations.

GRAPHIC

Capitalization Table as of March 31, 2025 Q1 2025 Results Conference Call || 6 Vireo Growth Inc. Capitalization Table* FD Treasury Method Shares Outstanding (@ stock price of US $0.50) 472,078,412 Stock Price US $0.45 Market Cap ($ USD) $212.4M Balance Sheet as of 3/31/25: Cash Balance $86.3M Net Long-Term Debt & Convertible Debt $72.5M Lease Liabilities $17.6M Income Tax Receivable $11.4M Uncertain Tax Liability $35.0M Subordinate Voting Shares* 339,475,288 Multiple Voting Shares 278,170 Total Subordinate Voting Shares (w/ Multiple Voting Shares Converted) 367,292,288 Options (@ avg. strike US $0.43) 30,731,300 Warrants (@ avg. strike US $0.82) 8,541,586 Grown Rogue Warrants (strike @ US $0.233) 10,000,000 RSUs 71,156,247 Convertible Debt 16,000,000 Total Shares Including All Dilutives 487,721,760 *Subordinate Voting Shares includes 129,536,874 shares issued related the private placement which was completed in December 2024.

GRAPHIC

EBITDA and Adjusted EBITDA Reconciliation Q1 2025 Results Conference Call || 7 Net income (loss) $ (6,508,790) $ (6,711,460) Interest expense, net 7,599,517 8,722,637 Income taxes 1,675,000 3,945,000 Depreciation & Amortization 257,134 253,581 Depreciation and amortization included in cost of goods sold 570,040 584,958 EBITDA (non-GAAP) $ 3,592,901 $ 6,794,716 Inventory adjustment $ 433,000 $ 304,000 Grown Rogue termination fee included in cost of goods sold 266,667 — Stock-based compensation 1,460,850 179,789 Transaction related expenses 1,244,696 — Other income (790,038) (1,327,879) Severance expense 379,916 — Loss on disposal of assets — 120,856 Adjusted EBITDA (non-GAAP) $ 6,587,992 $ 6,071,482 Three Months Ended March 31, 2025 2024

GRAPHIC

CSE: VREO OTCQX: VREOF